Company profile
Alzamend Neuro, Inc.
Pipeline2 assets
- AL001AL001 / LISPRO / ionic cocrystal of lithium, proline and salicylate / Neurology/PsychiatryAlzheimer's diseasePhase 2clinical developmentUSBipolar disorderPhase 2clinical developmentUSMajor depressive disorderPhase 2anticipated initiation in 2026US
- ALZN002ALZN002 / E22W / beta-amyloid / autologous mutant-peptide sensitized dendritic-cell therapeutic vaccine / NeurologyMild to moderate dementia of the Alzheimer's typePhase 1/2apaused in 2024; expected to resume by mid-2026US